Literature DB >> 7130243

Clinical data of granulosa cell tumors.

K W Schweppe, F K Beller.   

Abstract

Clinical data from Granulosa cell tumors (GCT) of the ovary were compared with data from 528 cases of malignant ovarian tumor in regard to symptomatology, treatment and prognosis. GCT are more frequent under the age of 30 and their biology requires a clinical separation from other feminizing mesenchymal tumors. Irregularities of uterine bleeding as a result of hormonal activity were the most frequent symptoms, explaining why their diagnosis is earlier than in ovarian cancer. The 5-year survival rates were similar when tumor stages were compared. GCT is associated with a frequency of late recurrences after 5, 10 or more years but a potential risk of malignancy is not related to clinical or histological criteria. Abdominal hysterectomy with bilateral salpingoophorectomy is standard treatment, whereas radiation and chemotherapy seem to be of little value.

Entities:  

Mesh:

Year:  1982        PMID: 7130243     DOI: 10.1007/bf00402064

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  28 in total

1.  Prognosis of granulosa cell tumours.

Authors:  S SJOSTEDT; T WAHLEN
Journal:  Acta Obstet Gynecol Scand Suppl       Date:  1961

2.  Granulosa-cell tumours causing precocious puberty; oestrogen fractionations in two patients.

Authors:  I BRUK; C P DANCASTER; W P JACKSON
Journal:  Br Med J       Date:  1960-07-02

3.  Granulosa cell tumor of the ovary; a clinical and pathologic review of 62 cases.

Authors:  J E HODGSON; M B DOCKERTY; R D MUSSEY
Journal:  Surg Gynecol Obstet       Date:  1945-12

4.  Malignant lesions of the uterus associated with estrogen-producing ovarian tumors.

Authors:  M B DOCKERTY; E MUSSEY
Journal:  Am J Obstet Gynecol       Date:  1951-01       Impact factor: 8.661

5.  Granulosa-theca cell tumors of the ovary associated with pregnancy. Case report and review of the literature.

Authors:  P N Gillibrand
Journal:  Am J Obstet Gynecol       Date:  1966-04-15       Impact factor: 8.661

6.  Ovarian cancer with special regard to radiotherapy.

Authors:  H L Kottmeier
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1971-02

7.  Chemotherapy in the treatment of cancer of the ovary.

Authors:  J P Smith; F Rutledge
Journal:  Am J Obstet Gynecol       Date:  1970-07-01       Impact factor: 8.661

8.  Prognosis of granulosa-theca tumors of the ovary.

Authors:  H J Norris; H B Taylor
Journal:  Cancer       Date:  1968-02       Impact factor: 6.860

9.  A clinicopathologic study of 92 cases of granulosa cell tumor of the ovary with special reference to the factors influencing prognosis.

Authors:  H Fox; K Agrawal; F A Langley
Journal:  Cancer       Date:  1975-01       Impact factor: 6.860

10.  [The prognosis of malignant ovarian tumours in correlation to the histological findings (author's transl)].

Authors:  S Sievers; G Dallenbach-Hellweg; D Susemihl; R Pohl
Journal:  Geburtshilfe Frauenheilkd       Date:  1981-01       Impact factor: 2.915

View more
  3 in total

1.  Clinicopathologic characteristics of granulosa cell tumors of the ovary: a multicenter retrospective study.

Authors:  In Ho Lee; Chel Hun Choi; Dae Gy Hong; Jae Yun Song; Young Jae Kim; Kyung Tai Kim; Kyu Wan Lee; Il Soo Park; Duk Soo Bae; Tae Jin Kim
Journal:  J Gynecol Oncol       Date:  2011-09-28       Impact factor: 4.401

2.  Clinical and genetic analysis of recurrent adult-type granulosa cell tumor of the ovary: Persistent preservation of heterozygous c.402C>G FOXL2 mutation.

Authors:  Satoshi Yanagida; Michael S Anglesio; Tayyebeh M Nazeran; Amy Lum; Momoko Inoue; Yasushi Iida; Hirokuni Takano; Takashi Nikaido; Aikou Okamoto; David G Huntsman
Journal:  PLoS One       Date:  2017-06-08       Impact factor: 3.240

3.  Is adjuvant chemotherapy beneficial for patients with FIGO stage IC adult granulosa cell tumor of the ovary?

Authors:  Dan Wang; Yang Xiang; Ming Wu; Keng Shen; Jiaxin Yang; Huifang Huang; Tong Ren
Journal:  J Ovarian Res       Date:  2018-03-27       Impact factor: 4.234

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.